Home Cart Sign in  
Chemical Structure| 1439901-97-9 Chemical Structure| 1439901-97-9

Structure of Tirabrutinib HCl
CAS No.: 1439901-97-9

Chemical Structure| 1439901-97-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ONO-4059 is a selective inhibitor of BTK with IC50 2.2 nm, ONO-4059 binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.

Synonyms: GS-4059 hydrochloride; ONO-4059 hydrochloride; ONO-WG-307

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tirabrutinib HCl

CAS No. :1439901-97-9
Formula : C25H23ClN6O3
M.W : 490.94
SMILES Code : O=C1N(C2=CC=C(OC3=CC=CC=C3)C=C2)C4=C(N)N=CN=C4N1[C@H]5CN(C(C#CC)=O)CC5.[H]Cl
Synonyms :
GS-4059 hydrochloride; ONO-4059 hydrochloride; ONO-WG-307
MDL No. :MFCD30187521
InChI Key :UQYDCIJFACDXSG-GMUIIQOCSA-N
Pubchem ID :71571562

Safety of Tirabrutinib HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Tirabrutinib HCl

RTK

Isoform Comparison

Biological Activity

Description
Tirabrutinib hydrochloride, known as ONO-4059 hydrochloride, is an orally bioavailable inhibitor of Bruton’s Tyrosine Kinase (BTK) capable of crossing the blood-brain barrier (BBB), with an IC50 of 6.8 nM. It forms an irreversible and covalent bond with BTK, inhibiting abnormal B cell receptor signaling pathways. This property makes tirabrutinib hydrochloride applicable for research into autoimmune diseases and hematological cancers[1].[2].[3].[4].

In Vitro:

Cell Line
Concentration Treated Time Description References
Mouse splenic B cells 5 μM 48 h Inhibition of BTK activation, reducing CD1dhiCD5+ Breg cell differentiation and expression of IL-10 and IL-35 PMC6486434
Human peripheral blood neutrophils 0, 2.5, 5.0, 10, 25, 50, 100 nM 1 h To evaluate the effect of Tirabrutinib on MPO and anti-MPO antibody complex-induced neutrophil extracellular trap (NET) formation. Results showed that Tirabrutinib suppressed NET formation in a dose-dependent manner, with significant suppression at 10 nM. PMC10626711

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice KrasG12D-PDEC orthotopic pancreatic cancer model Oral 10 mg/kg Once daily for 2 or 4 weeks Inhibition of BTK activation, reducing the accumulation of CD1dhiCD5+ Breg cells, increasing CD8+IFNγ+ cytotoxic T cells, and significantly inhibiting tumor cell proliferation and PanIN growth PMC6486434
Rats Experimental microscopic polyangiitis (MPA) model Oral 0.0037% or 0.012% Daily, for 42 days To evaluate the therapeutic effect of Tirabrutinib on experimental MPA. Results showed that Tirabrutinib ameliorated MPA in a dose-dependent manner, reducing NET-forming neutrophils without affecting MPO-ANCA titer. PMC10626711

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.04mL

0.41mL

0.20mL

10.18mL

2.04mL

1.02mL

20.37mL

4.07mL

2.04mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories